Next Article in Journal
The Importance of Succinylacetone: Tyrosinemia Type I Presenting with Hyperinsulinism and Multiorgan Failure Following Normal Newborn Screening
Previous Article in Journal
Newborn Screening Protocols and Positive Predictive Value for Congenital Adrenal Hyperplasia Vary across the United States
Previous Article in Special Issue
Assessing the Performance of Dried-Blood-Spot DNA Extraction Methods in Next Generation Sequencing
Open AccessArticle

National Program for External Quality Assessment of Chinese Newborn Screening Laboratories

by Yuxuan Du 1,2,3, Wei Wang 1,2,3, Jiali Liu 1,2,3, Zhixin Zhang 1,2,3, Zhen Zhao 1,2,3, Falin He 1,2,3, Shuai Yuan 1,2,3 and Zhiguo Wang 1,2,3,*
National Center for Clinical Laboratories, Beijing Hospital, Beijing 100730, China
National Center of Gerontology, Beijing Hospital, Beijing 100730, China
Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China
Author to whom correspondence should be addressed.
Int. J. Neonatal Screen. 2020, 6(2), 38;
Received: 23 March 2020 / Revised: 4 May 2020 / Accepted: 5 May 2020 / Published: 9 May 2020
Objectives: To analyze the coefficient of variation (CV) of external quality assessment (EQA) in Chinese newborn screening (NBS) laboratories. Method: EQA’s robust CV was analyzed by the Clinet-EQA evaluation system. Results: Participating laboratories of the EQA program increased annually. There was more than a 11-fold increase in phenylalanine (Phe) and thyroid stimulating hormone (TSH). It has shown a declining robust CV, which has tended to level off in recent years. The interquartile range (IQR) of Phe and TSH’s robust CV has decreased from 15.5% to 1.5% and from 22.8% to 1.8%, respectively. Compared to bacterial inhibition assay (BIA), the robust CV of Phe has been shown to be relatively reduced in the fluorescence assay and quantitative enzymatic assay (QEA). The robust CV by ELISA was relatively unstable compared to DELFIA and FEIA. In addition, the robust CVs of glucose-6-phosphate dehydrogenase (G6PD) and 17-alpha-hydroxy progesterone (17-OHP) by Genetic Screening Processor (GSP) were lower than other systems. The median of robust CV by non-derivatized MS/MS (Fenghua) in Phe and free carnitine were around 2.2–4.7% and 2.6–5.2%. Conclusion: Neonatal screening has developed rapidly in China and the majority of participant laboratories had satisfactory performance for the quantitative results. View Full-Text
Keywords: newborn screening; external quality assessment; coefficient of variation newborn screening; external quality assessment; coefficient of variation
Show Figures

Figure 1

MDPI and ACS Style

Du, Y.; Wang, W.; Liu, J.; Zhang, Z.; Zhao, Z.; He, F.; Yuan, S.; Wang, Z. National Program for External Quality Assessment of Chinese Newborn Screening Laboratories. Int. J. Neonatal Screen. 2020, 6, 38.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop